KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables: 2010-2025

Historic Receivables for Rigel Pharmaceuticals (RIGL) over the last 9 years, with Sep 2025 value amounting to $46.0 million.

  • Rigel Pharmaceuticals' Receivables rose 50.39% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.6 million, marking a year-over-year increase of 11.13%. This contributed to the annual value of $41.6 million for FY2024, which is 36.22% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Receivables of $46.0 million as of Q3 2025, which was up 15.06% from $40.0 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Receivables ranged from a high of $142.2 million in Q1 2021 and a low of $3.1 million during Q1 2025.
  • Moreover, its 3-year median value for Receivables was $29.4 million (2023), whereas its average is $29.3 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 1,372.00% in 2021, then crashed by 89.28% in 2022.
  • Rigel Pharmaceuticals' Receivables (Quarterly) stood at $15.5 million in 2021, then increased by 29.27% to $20.0 million in 2022, then skyrocketed by 52.75% to $30.6 million in 2023, then surged by 36.22% to $41.6 million in 2024, then soared by 50.39% to $46.0 million in 2025.
  • Its Receivables stands at $46.0 million for Q3 2025, versus $40.0 million for Q2 2025 and $3.1 million for Q1 2025.